Stockreport

SciSparc's subsidiary MitoCareX approved for acquisition by N2OFF shareholders; shares up 29% [Seeking Alpha]

SciSparc Ltd.  (SPRC) 
PDF Upon closing, MitoCareX will become a wholly owned subsidiary of N2OFF, focused on mitochondrial protein-targeted therapies for hard-to-treat cancers. Deal terms incl [Read more]